Globus Medical, Inc. (NYSE:GMED) will be issuing its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of $0.30 per share for the quarter.
Globus Medical (NYSE:GMED) last released its earnings results on Wednesday, August 2nd. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.02. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The company had revenue of $152.39 million for the quarter, compared to analysts’ expectations of $150.94 million. During the same quarter last year, the business earned $0.29 EPS. The firm’s revenue was up 10.8% compared to the same quarter last year. On average, analysts expect Globus Medical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of Globus Medical, Inc. (GMED) opened at $31.36 on Friday. Globus Medical, Inc. has a one year low of $19.25 and a one year high of $34.03. The company has a market cap of $3,020.00, a P/E ratio of 25.29, a price-to-earnings-growth ratio of 2.37 and a beta of 0.54.
A number of brokerages have issued reports on GMED. BidaskClub lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Globus Medical in a report on Tuesday, July 11th. Zacks Investment Research raised shares of Globus Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Barclays PLC reaffirmed an “underweight” rating and set a $28.00 price objective (down from $30.00) on shares of Globus Medical in a report on Thursday, August 3rd. Finally, Oppenheimer Holdings, Inc. set a $35.00 price objective on shares of Globus Medical and gave the company a “hold” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $30.57.
In related news, insider A Brett Murphy sold 15,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $29.99, for a total value of $449,850.00. Following the completion of the transaction, the insider now directly owns 101,217 shares of the company’s stock, valued at $3,035,497.83. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 28.21% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.com-unik.info/2017/11/05/globus-medical-inc-gmed-to-release-quarterly-earnings-on-monday.html.
Globus Medical Company Profile
Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.
What are top analysts saying about Globus Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Globus Medical Inc. and related companies.